Haleon (HLN) FCF Margin (2021 - 2025)

Haleon's (HLN) quarterly FCF Margin came in at 1.75% in Q4 2025, up 22.57% on a QoQ basis from 1.43% in Q4 2023.

Haleon (HLN) FCF Margin (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of FCF Margin data on file, last reported at 1.75% in Q4 2025.

Quarterly FCF Margin changed N/A year-over-year to 1.75% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.12% (changed N/A YoY) and the FY2025 annual result came in at 20.96%, up 270.0% from the prior year.
FCF Margin rose to 1.75% in Q4 2025, from 1.43% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 1.75% in Q4 2025 to a low of 347.66% in Q4 2022.
A 4-year average of 85.8% and a median of 1.34% in 2023 frame the typical range for FCF Margin.
Annual changes were most pronounced in 2022 — FCF Margin tumbled 34892 bps — and 2023, when it soared 34909 bps.
Tracing HLN's FCF Margin over 4 years: stood at 1.26% in 2021, then slumped by 27698 bps to 347.66% in 2022, then jumped by 100 bps to 1.43% in 2023, then rose by 23 bps to 1.75% in 2025.
The last three FCF Margin figures came in at 1.75% (Q4 2025), 1.43% (Q4 2023), and 347.66% (Q4 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	7.41%
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	21.80%
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	14.87%
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	26.25%
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	8.76%
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	13.41%
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	17.84%
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn	27.63%

Download Data